Epidermolysis Bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Epidermolysis Bullosa (EB)

Epidermolysis bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Epidermolysis bullosa (EB) is a group of inherited diseases that are characterised by blistering lesions on the skin and mucous membranes.

Classification-there are four major types of EB based on different sites of blister formation within the skin structure:

Epidermolysis bullosa simplex (EBS) - Epidermis or uppermost layer of skin cells (keratinocytes), Junctional epidermolysis bullosa (JEB)- Lamina lucida within the basement membrane zone, Dystrophic epidermolysis bullosa (DEB)- Lamina densa and upper dermis, Kindler syndrome- Mixed pattern or multiple levels within and beneath the basement membrane zone.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence rate of Epidermolysis bullosa (EB) is between a range of 10.8 to 11.4 per one million live births with an incidence of 1 in every 51,000 live births.

Competitive landscape of Epidermolysis bullosa (EB) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Epidermolysis bullosa (EB) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Epidermolysis bullosa (EB) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Epidermolysis Bullosa (EB) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Partner Phase
1 FCX-007 Castle Creek Pharmaceuticals LLC Intrexon; Fibrocell Science III
2 RGN-137 G-treeBNT Co., Ltd Lee's Pharmaceutical; RegeneRx II
3 EB-101 Abeona Therapeutics, Inc. N/A I/II
4 KB103 Krystal Biotech, Inc. N/A I/II
5 PTR-01 BridgeBio Inc. N/A I/II
6 QR-313 Wings Therapeutics N/A I/II
7 Topical 31510 Berg Pharma, LLC N/A I
8 S-005151 Shionogi & Co. Ltd. StemRIM Investigator Initiated
9 Serlopitant Menlo Therapeutics, Inc. VPD Investigator Initiated
10 AC-201 TWi Pharmaceuticals, Inc. N/A Development Outside U.S.
11 allo-APZ2 TICEBA GmbH N/A Development Outside U.S.
12 CCP-020 Castle Creek Pharmaceuticals LLC TWi Pharmaceuticals Development Outside U.S.
13 CL-2020 Mitsubishi Tanabe Pharma Corporation N/A Development Outside U.S.
14 Episalvan Amryt Pharma plc N/A Development Outside U.S.
15 INM-755 InMed Pharmaceuticals Ltd. N/A Development Outside U.S.
16 Prochymal Mesoblast Limited JCR Pharmaceuticals; Mallinckrodt; Smith & Nephew Development Outside U.S.
17 TXA127 Constant Therapeutics, LLC Unigene Laboratories Preclinical